Last reviewed · How we verify
Fluvastatin 20 MG
At a glance
| Generic name | Fluvastatin 20 MG |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas (PHASE1)
- Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome (PHASE2)
- Drug-Drug Interaction Between Rifampin and Fluvastatin (PHASE4)
- A Study of LY3015014 in Participants With High Cholesterol (PHASE2)
- Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination (NA)
- High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly (PHASE3)
- Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan (NA)
- High Potency Statins and Acute Kidney Injury
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluvastatin 20 MG CI brief — competitive landscape report
- Fluvastatin 20 MG updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI